Drug Profile
Research programme: Nose disorder therapeutics - Altamira Therapeutics
Alternative Names: AM 123Latest Information Update: 13 Sep 2021
Price :
$50
*
At a glance
- Originator Auris Medical
- Developer Altamira Therapeutics
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Nose disorders
Most Recent Events
- 16 Jul 2021 Auris Medical is now called Altamira Therapeutics
- 28 Oct 2018 No recent reports of development identified for preclinical development in Nose-disorders in Switzerland
- 15 Sep 2014 Preclinical trials in Nose disorders in Switzerland (unspecified route)